SCHEMBL2955191

SCHEMBL2955191

Cc1cc(C#CCN2CCOCC2)ccc1N

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.45
MAPK14 Q16539 2/20 0.41
CSF1R P07333 1/20 0.41
EGFR P00533 1/20 0.39
MMP13 P45452 1/20 0.39
TLR8 Q9NR97 1/20 0.39
HRH3 Q9Y5N1 5/20 0.38
KDM4E B2RXH2 1/20 0.38
GLA P06280 1/20 0.38
HTT P42858 1/20 0.38
GAA P10253 1/20 0.38
RAD52 P43351 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
KCNJ5 P48544 1/20 0.37
KCNJ3 P48549 1/20 0.37
SLC6A4 P31645 1/20 0.37
CYP2A13 Q16696 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3707475 0.87 LMNA (0.49) LMNACSF1REGFRMMP13HRH3
SCHEMBL13178118 0.86 LMNA (0.60) LMNAMAPK14EGFRMMP13HRH3
SCHEMBL13178119 0.83 LMNA (0.45) LMNAHRH3GAARAD52
SCHEMBL24474658 0.79 LMNA (0.58) LMNAMAPK14HRH3KDM4EHTT
SCHEMBL30881164 0.78 MAPK14 (0.44) LMNAMAPK14CSF1RMMP13KDM4E
SCHEMBL28393218 0.76 LMNA (0.58) LMNAMAPK14EGFRHRH3KDM4E
SCHEMBL2955389 0.74 TLR8 (0.46) MAPK14TLR8KDM4EGLAHTT
SCHEMBL24474667 0.73 LMNA (0.58) LMNAMAPK14EGFRMMP13HRH3
SCHEMBL2946209 0.73 TLR8 (0.37) MAPK14CSF1REGFRMMP13TLR8
SCHEMBL3634873 0.72 LMNA (0.56) LMNAHRH3MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120122840-A1 COMPOUNDS AND THERAPEUTIC USES THEREOF MYREXIS, INC. (US) 2012-05-17 US disclosed
US-20120122840-A1 COMPOUNDS AND THERAPEUTIC USES THEREOF MYREXIS, INC. (US) 2012-05-17 US disclosed
WO-2010111406-A2 COMPOUNDS AND THERAPEUTIC USES THEREOF MYRIAD PHARMACEUTICALS, INC. (US) 2010-09-30 WO disclosed
WO-2010111406-A2 COMPOUNDS AND THERAPEUTIC USES THEREOF MYRIAD PHARMACEUTICALS, INC. (US) 2010-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122840-A1 COMPOUNDS AND THERAPEUTIC USES THEREOF VHL, TP53, ASAH2 LMNA 2130/4885MAPK14 4708/4885CSF1R 4296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.